I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Diabetic Macular Edema: Protecting Your Central Vision
Understanding Diabetic Macular Edema
DME occurs when fluid builds up inside the macula, the part of the retina responsible for sharp, central vision. Knowing what causes this swelling helps explain why early monitoring and timely care matter so much.
The macula is a small but essential area at the center of the retina, the light-sensitive tissue lining the back of the eye. It is responsible for the detailed central vision you use for reading, driving, recognizing faces, and performing close-up tasks. When the macula swells with fluid, these everyday activities can become difficult or impossible.
Over time, elevated blood sugar levels damage the tiny blood vessels running throughout the retina. This weakens vessel walls and breaks down the blood-retinal barrier, a protective layer that normally prevents fluid from leaking into retinal tissue. When that barrier is compromised, fluid and proteins seep into the surrounding tissue and cause swelling.
The process is driven in part by retinal hypoxia, meaning the retina is not receiving enough oxygen. In response, the body produces higher levels of vascular endothelial growth factor, or VEGF, a protein that triggers new blood vessel growth. These newly formed vessels are fragile and prone to leaking, which worsens the fluid buildup in the macula.
Diabetic retinopathy is the broader term for the damage diabetes causes to retinal blood vessels across the entire retina. Diabetic macular edema is a specific complication that can develop at any stage of diabetic retinopathy, from mild to advanced. Not every person with diabetic retinopathy will develop DME, but the risk increases as retinopathy becomes more severe. Both type 1 and type 2 diabetes can lead to this condition.
Low oxygen levels in damaged retinal tissue trigger the release of a protein called vascular endothelial growth factor, or VEGF. VEGF causes blood vessels to leak fluid into the macula and can stimulate the growth of fragile, abnormal blood vessels that leak even more easily. Inflammation within the retina adds to the swelling, while microaneurysms (tiny bulges in weakened vessel walls) and scar tissue formation contribute further to the edema. Understanding this pathway is important because the main treatments for DME are designed to block VEGF and reduce inflammation.
Who Is Affected and Risk Factors
DME does not affect every person with diabetes equally. Several factors influence individual risk, and understanding them helps guide how closely your eyes should be monitored over time.
DME affects a significant portion of the diabetic population in the United States. According to the National Eye Institute, approximately 1 in 15 people with diabetes will develop the condition at some point. The impact on daily life and central vision makes routine eye screening one of the most valuable steps a person with diabetes can take.
The longer a person has lived with diabetes, the greater the likelihood of developing DME. This relationship between disease duration and retinal complications is well established and is a primary reason why ongoing monitoring becomes increasingly important over the years. People diagnosed at a younger age face a longer cumulative period of exposure to elevated blood sugar, which raises their lifetime risk.
Poor blood sugar control is among the strongest risk factors for DME. Glycated hemoglobin, known as HbA1c, reflects average blood sugar levels over several months and is a key indicator of how well diabetes is being managed. Keeping HbA1c within the target range set by your primary care provider or endocrinologist is directly tied to reduced retinal vessel damage. High blood pressure and elevated cholesterol also damage blood vessels in the retina and increase the likelihood of fluid leaking into the macula.
Beyond blood sugar, blood pressure, and cholesterol, several additional factors can raise the risk of developing DME.
- The presence and severity of existing diabetic retinopathy
- Diabetic kidney disease, which signals widespread damage to small blood vessels throughout the body
- Pregnancy in women with diabetes, which can temporarily worsen retinopathy and macular swelling
- Ethnicity, with higher rates observed in Hispanic and African American populations
Knowing your personal risk profile helps your care team determine the right frequency for eye examinations.
Symptoms and Warning Signs
One of the most challenging aspects of DME is that it can progress quietly before causing noticeable vision changes. Recognizing the symptoms and knowing when to seek urgent care is a critical part of protecting your eyesight.
DME can develop in one eye or both eyes. Sometimes one eye has noticeable symptoms while the other appears unaffected, but early swelling may still be present in the "good" eye without causing any change in vision. A retina specialist can detect changes in both eyes during a comprehensive dilated examination, which is why routine screening is important even when only one eye feels affected.
In the early stages of DME, fluid in the macula may be too limited to affect vision in any obvious way. Many patients have no symptoms at all during this phase. This is one of the primary reasons why routine dilated eye exams are so important for anyone living with diabetes. Significant damage can be occurring even when your vision feels entirely normal.
As DME progresses, it begins to affect the central vision needed for detailed tasks. The following changes are commonly reported by patients.
- Blurred or distorted central vision
- Difficulty reading or making out fine print
- Trouble recognizing faces
- Colors that appear washed out or faded
- Dark or empty areas at the center of your visual field
These changes may affect one or both eyes. Without treatment, chronic macular swelling can cause irreversible damage and lasting central vision loss. Any new or sudden change in vision should be evaluated promptly by a retina specialist.
The sooner DME is identified, the greater the range of treatment options available and the better the chances of preserving vision. Waiting until symptoms become severe often means some damage has already occurred that is difficult to reverse. Routine screening gives your retina specialist the best opportunity to identify changes before significant vision loss has taken place.
How DME Is Diagnosed
Diagnosing DME involves a combination of clinical examination and advanced imaging. Our retina specialists use current diagnostic technology to build a complete picture of what is happening in your macula and the surrounding retinal tissue.
A retina specialist begins with a dilated eye exam. Special drops are used to widen the pupil, allowing a detailed view of the retina and macula. This examination can reveal signs of fluid buildup, blood vessel damage, and structural changes associated with diabetic retinopathy and DME.
Optical coherence tomography, known as OCT, is a noninvasive imaging test that produces detailed, cross-sectional pictures of the retina. It allows the retina specialist to precisely measure the thickness of the macula and detect even small amounts of fluid. OCT is one of the most important tools for both diagnosing DME and tracking how a patient responds to treatment over time.
In fluorescein angiography, a harmless dye is injected into a vein in the arm. As the dye travels through the retinal blood vessels, a specialized camera captures images showing exactly where leakage is occurring. This test helps the retina specialist identify damaged vessels and develop the most targeted treatment approach for each patient.
A visual acuity test measures how clearly you can see at different distances. On its own, this test cannot diagnose DME, but it helps establish how much central vision has already been affected and provides a baseline for measuring whether treatment is producing improvement. Your retina specialist will combine this information with imaging findings to guide your care plan.
Treatment Options for DME
Several effective treatments are available for DME, and the right approach depends on factors specific to your eyes and overall health. Every treatment plan is individualized based on imaging results, disease severity, and how your eyes respond to therapy over time.
Anti-VEGF injections are the established first-line treatment for diabetic macular edema. These medications are delivered directly into the eye in a procedure called an intravitreal injection. By blocking the VEGF protein responsible for promoting abnormal, leaky blood vessel growth, these injections reduce swelling in the macula and can improve or stabilize vision.
Several anti-VEGF medications are FDA-approved for DME, including ranibizumab (Lucentis), aflibercept (Eylea), and faricimab (Vabysmo). Bevacizumab (Avastin) is also commonly used in an off-label capacity. Each medication has its own dosing schedule, and your retina specialist will recommend the option best suited to your individual situation.
High-dose aflibercept (Eylea HD) is an FDA-approved option that offers the potential for extended treatment intervals. After completing an initial treatment phase, patients who respond well may be dosed as infrequently as every 20 weeks. This extended schedule can significantly reduce the number of injections and office visits required each year while still maintaining the benefits of anti-VEGF therapy.
For some patients, inflammation plays a central role in driving DME, and corticosteroid therapy may be more effective than anti-VEGF injections alone. Options include the dexamethasone implant (Ozurdex), a biodegradable implant that releases medication inside the eye over several months, and the fluocinolone acetonide implant (Iluvien), which can provide sustained steroid delivery for up to three years. Corticosteroids may be recommended when anti-VEGF therapy has not produced adequate results, or as part of a combined treatment approach.
Laser photocoagulation uses a focused beam of light to seal leaking blood vessels and reduce fluid accumulation in the macula. It was once the primary treatment for DME, but anti-VEGF injections have largely replaced laser as the first-line approach. Laser therapy may still be used in combination with injections or in specific situations where injections alone have not been sufficient.
Susvimo is a surgically implanted device that continuously delivers ranibizumab, an anti-VEGF medication, directly inside the eye. It is designed for patients who have already responded well to at least two intravitreal anti-VEGF injections. The device is periodically refilled by a retina specialist during a brief office visit, reducing the need for repeated individual injections in appropriately selected patients.
Several FDA-approved anti-VEGF medications are currently used to treat DME:
-
Lucentis (ranibizumab) — the first anti-VEGF medication FDA-approved for DME
-
Eylea (aflibercept) — typically given every 4 to 8 weeks
-
Eylea HD — a higher-dose formulation that can extend intervals up to 5 months
-
Vabysmo (faricimab) — dosing intervals ranging from 4 to 16 weeks
-
Avastin (bevacizumab) — used off-label, often as a cost-effective option
-
Susvimo (ranibizumab port delivery system) — approved in 2025, a surgically implanted device that delivers medication continuously
Your retina specialist will recommend the option best suited to your disease pattern, treatment history, and lifestyle.
Recent advances have focused on reducing the burden of frequent injections. According to the FDA, research has shown that 71 percent of DME patients can achieve dosing intervals of 16 weeks or longer with certain newer therapies. The Susvimo port delivery system represents another major step forward, offering continuous medication delivery with only two refill visits per year. These innovations make long-term treatment more manageable while maintaining strong vision outcomes.
What to Expect During Treatment
Many patients feel understandably anxious about receiving injections in the eye. Understanding what each step actually involves, and what to expect as treatment continues, can help ease that concern before your first appointment.
Intravitreal injections are performed in the retina specialist's office and take only a few minutes from start to finish. Anesthetic drops are applied beforehand to numb the surface of the eye. Most patients report brief pressure or mild discomfort during the procedure rather than significant pain. Some redness, mild soreness, or new floaters may appear in the hours that follow, but these effects generally resolve on their own within a few days.
DME treatment typically begins with a loading phase of monthly injections designed to reduce fluid in the macula as effectively as possible. After this initial period, the interval between appointments may be extended based on how the eye is responding. Your retina specialist will use OCT images and visual acuity results at each visit to guide these decisions. Staying consistent with follow-up is essential, because macular fluid can return if treatment is reduced too quickly or stopped prematurely.
Anti-VEGF treatment can stabilize vision in most patients and improve visual clarity in many others. Results depend on how long DME has been present, the severity of the swelling, and how well blood sugar is being managed. Some patients experience meaningful gains in vision, while others see stabilization that prevents further decline. Complete restoration of pre-disease vision is not typical, but protecting functional central vision is an achievable goal with consistent treatment and follow-up.
Living With Diabetic Macular Edema
Managing DME is not only about the treatments received in the office. Daily habits, overall health management, and emotional well-being all play a meaningful role in how vision holds up over time.
Controlling blood sugar is one of the most powerful things you can do alongside medical treatment to slow DME progression. Keeping your HbA1c within the target range set by your primary care doctor or endocrinologist limits ongoing damage to the retinal blood vessels that drive the disease. Managing blood pressure and cholesterol through medication, nutrition, and regular physical activity also supports retinal health and can improve your overall response to eye treatment.
If DME has affected your central vision, practical adjustments can help you maintain independence and quality of life. Large-print materials, magnifying devices, improved lighting, and high-contrast display settings on phones or computers can make everyday tasks considerably easier. A low vision specialist can provide a personalized assessment and recommendations based on your specific level of vision.
Living with a condition that affects vision can bring genuine emotional challenges, including stress, frustration, and worry about the future. These feelings are a normal response to a serious diagnosis. Support groups for people with diabetic eye disease, counseling services, and open conversations with your care team can all make a meaningful difference. Staying well-informed about your condition and treatment plan tends to give patients a greater sense of confidence and control.
Even when DME appears well controlled, ongoing monitoring remains necessary. Macular fluid can return months or years after successful treatment, and new areas of leakage may develop over time. People with diabetes should have at least one dilated eye exam per year, and those diagnosed with DME or diabetic retinopathy will typically need more frequent visits. Keeping every scheduled appointment is one of the most effective ways to protect the vision you have.
When to See a Retina Specialist
Knowing when to seek routine care versus urgent evaluation can make a critical difference for your vision. Whether you were recently diagnosed with diabetes or have lived with the condition for many years, the following guidance applies to you.
Every person with type 1 or type 2 diabetes should have regular dilated eye exams. The American Academy of Ophthalmology recommends that people with type 2 diabetes receive an eye exam at the time of diagnosis. People with type 1 diabetes should have their first dilated exam within five years of being diagnosed. A retina specialist can perform these screenings and identify problems early, when treatment is most effective.
Certain vision changes require immediate attention and should not wait for a scheduled appointment. Seek care from a retina specialist or go to an emergency room right away if you experience any of the following.
- A sudden increase in floaters or a shower of new spots in your vision
- Flashes of light, particularly in your peripheral vision
- A dark curtain or shadow spreading across any part of your visual field
- Sudden vision loss in one eye
These symptoms may indicate a retinal tear, detachment, or another serious condition that requires prompt evaluation to prevent lasting vision loss.
If you are receiving treatment for DME but your vision continues to decline or fluid persists on imaging, speak openly with your retina specialist about alternative options. Switching to a different anti-VEGF medication, adding corticosteroid therapy, or combining treatment approaches may produce better results. An ongoing dialogue with your specialist about how your eye is responding is one of the most important parts of managing this condition over the long term.
The American Academy of Ophthalmology recommends that adults with type 2 diabetes have a comprehensive dilated eye exam at the time of diagnosis and every year thereafter. Adults with type 1 diabetes should begin annual exams within five years of their diagnosis. Women who are pregnant or planning pregnancy should be examined more frequently, as retinopathy and macular swelling can progress more quickly during pregnancy. Your eye care provider may recommend more frequent visits depending on your personal risk profile.
Not every symptom of DME appears suddenly. If you notice new blurriness, increasing difficulty reading, or changes in the way you perceive colors, schedule an appointment with your retina specialist as soon as possible. Gradual changes warrant prompt evaluation, ideally before significant damage occurs, because early treatment produces the best long-term vision outcomes.
Frequently Asked Questions
The following questions address practical concerns that patients frequently raise about living with and managing DME.
Treatment can produce significant vision improvement for many patients, but DME is generally managed as a long-term condition rather than permanently eliminated. If fluid has been present in the macula for an extended period, some structural changes to the retinal tissue may be difficult to fully reverse even with successful therapy. Starting treatment early, before lasting damage accumulates, gives the best opportunity for meaningful visual recovery. Continued monitoring is necessary even after fluid resolves, because the condition can return.
Treatment frequency is determined by how your individual eye responds, not by a single universal protocol. Most plans begin with monthly injections for the first several months, after which your specialist may gradually extend the interval between visits. Some patients do well with injections every two to four months over the long term, while others require more frequent care. Your OCT measurements and visual acuity results at each visit serve as the most reliable guide for adjusting your schedule and determining when intervals can safely be extended.
Yes, and significantly so. While managing blood sugar alone will not resolve existing macular fluid, keeping your HbA1c stable limits the ongoing vessel damage that sustains the disease. Good systemic control works alongside eye treatment to slow progression and may reduce how frequently fluid returns after a course of therapy. Patients who manage their diabetes consistently over time tend to experience better long-term visual outcomes than those whose blood sugar remains poorly controlled.
Diabetic retinopathy is the broader category of damage that diabetes causes to blood vessels across the entire retina. Diabetic macular edema is one specific consequence of that process, occurring when leaking vessels allow fluid to accumulate in the macula and disrupt central vision. You can have diabetic retinopathy without developing DME, but DME always develops within the context of retinopathy. The two conditions may require different or additional treatments and are each monitored separately at your visits.
Anti-VEGF injections have been used to treat retinal conditions for close to two decades, and the accumulated safety data over that period are reassuring for ongoing use. As with any procedure, there are small risks associated with intravitreal injections, including infection, bleeding inside the eye, and temporary increases in eye pressure. Serious complications are uncommon. Your retina specialist monitors your eye health carefully at every visit and will address any concerns about continuing therapy. For most patients with DME, the benefit of preserving central vision well outweighs these manageable risks.
Yes. Because DME results from systemic diabetes affecting blood vessels throughout the body, it can develop in both eyes, either simultaneously or at different points during the course of the disease. One eye may be more severely affected than the other, and each eye may respond differently to treatment. Your retina specialist will evaluate both eyes at every visit and develop an individualized plan for each based on its current condition. Monitoring both eyes is always part of a complete diabetic eye care evaluation.
There is no guaranteed way to prevent DME, but taking action on known risk factors gives you the best chance of avoiding it or catching it very early. Keeping HbA1c within your target range, controlling blood pressure and cholesterol, avoiding tobacco, and maintaining annual dilated eye exams are the most effective protective steps. For people already living with diabetic retinopathy, close monitoring allows treatment to begin before swelling threatens central vision.
A diagnosis of DME does not mean that serious vision loss is inevitable. With the treatments currently available, most patients are able to maintain useful vision, and many experience real improvement in their clarity of sight. Prompt treatment, consistent adherence to your injection schedule, and careful diabetes management provide the strongest protection against long-term vision loss.
Schedule an Evaluation at New England Retina Associates
If you have diabetes and have not recently had a dilated eye exam, or if you have been referred for evaluation of diabetic macular edema, we encourage you to reach out to New England Retina Associates. Our fellowship-trained retina specialists serve patients across Connecticut with the advanced diagnostic technology, treatment experience, and individualized attention this condition requires. We welcome both referred and self-referred patients and are available for urgent evaluations when vision changes call for prompt attention. Early evaluation is one of the most important steps you can take toward protecting your central vision for years to come.
30 Years of Care & Commitment
